Hepatocellular carcinoma
Conditions
Interventions
Triple therapy group:None
Binary therapy group:None
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Ages 18-75, male or female; 2. Patients who have been enrolled in the clinical research cohort (a randomized controlled study of HAIC combined with carlimlimab and apatinib for conversion therapy in patients with potentially resectable hepatocellular carcinoma, protocol number: MA-HCC-II/III-026); 3. They had basic cognitive function and could understand the content of psychological assessment questionnaire;
Exclusion criteria
Exclusion criteria: 1. There are serious heart, lung, kidney and other important organ dysfunction or hepatic encephalopathy, intractable ascites and other late complications; 2. Comorbid psychiatric or neurological diseases, such as major depression, schizophrenia, epilepsy, alcohol abuse, drug abuse, cognitive dysfunction, etc; 3. Pregnant women, lactating women, or those who have family planning plans but refuse to take effective contraceptive measures; 4. Other intervention psychotherapy, antipsychotic intervention, and other treatments that may interfere with the evaluation were received during the study; 5. The researchers identified other cases that were not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Surgical conversion success rate;Mental Health; | — |
Secondary
| Measure | Time frame |
|---|---|
| Laboratory indicators;Quality of life; | — |
Countries
China
Contacts
Public ContactWu Xiaojun
Zhongshan Hospital, Fudan University
Outcome results
None listed